



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

LSKL TFA


Chemical Properties

CAS No. :

Formula: C₂₃H₄₃F₃N₆O₇

Molecular Weight: 572.62

Appearance: no data available

Storage: keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	LSKL TFA (H-Leu-Ser-Lys-Leu-NH ₂ TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.
Targets(IC50)	TGF-beta/Smad
In vitro	LSKL TFA from the latent form of TGF-β is responsible for the interaction with the KTRF sequence from ADAMTS1, leading to TGF-β activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTRF sequence, characterized by 3 salt bridges and 2 hydrogen bonds. [3]
In vivo	Intraperitoneal injection of 1 mg/kg LSKL TFA, into male rats exerted a protective effect against subarachnoid fibrosis, attenuated ventricular enlargement, and effectively inhibited the development of hydrocephalus. [1] Intraperitoneal injection of 30 mg/kg LSKL TFA, was able to successfully inhibit the Smad signaling pathway activated by transforming growth factor-β (TGF-β) after partial hepatectomy. LSKL effectively attenuated the activation of TGF-β-Smad signaling by antagonizing TSP-1 rather than reducing TSP-1 protein expression. [2]

Solubility Information

Solubility	DMSO: 200 mg/mL, (349.27 mM.),Sonication is recommended. H ₂ O: 80 mg/mL (139.71 mM.),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7464 mL	8.7318 mL	17.4636 mL
5 mM	0.3493 mL	1.7464 mL	3.4927 mL
10 mM	0.1746 mL	0.8732 mL	1.7464 mL
50 mM	0.0349 mL	0.1746 mL	0.3493 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF- β 1 signaling activity following subarachnoid hemorrhage in rats. *Exp Ther Med*. 2016 Oct;12(4):2537-2543.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481